Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative treatments for serious medical conditions. The company's research primarily focuses on immunotherapy, with the intent to harness the body's own immune system to combat diseases. Faron Pharmaceuticals has been actively engaged in developing novel therapies within the realms of immuno-oncology and acute organ failure, addressing critical unmet medical needs. The company is particularly known for its flagship product candidates aimed at treating various forms of cancer and life-threatening conditions such as acute respiratory distress syndrome. Headquartered in Turku, Finland, Faron Pharmaceuticals has carved a niche for itself by focusing on biologic and drug candidates that target distinct cellular pathways involved in immune signaling. The company's contributions are particularly impactful in the biotechnology sector, where it collaborates with research institutions and leverages extensive clinical expertise to push the boundaries of medical science. Faron Pharmaceuticals plays a vital role in the pharmaceutical industry by advancing potential solutions that may transform the landscape of disease management and enhance patient outcomes globally.
€0.48
€0.00 (-0.11%)
EOD Jul 2, 2026
Negative free cash flow of -€18M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€27M
▼ -5.2% YoY
Op. Margin
—
ROIC
-81.42%
▲ +35.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€18M
▲ +19.5% YoY
Op. Cash Flow (TTM)
-€16M
▲ +27.7% YoY
Net Debt
€12M
Cash & Equiv.
€12M
Continue Research
Faron Pharmaceuticals Oy (FARON.XHEL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Faron Pharmaceuticals Oy scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Faron Pharmaceuticals Oy scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -81.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh FARON.XHEL's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.